MedAdvisor Limited

Hi everyone.

Hello. Okay, so the format for today is Rick and Ancilla will walk us through the results which were released this morning to the ASX. They're also up on the MedAdvisor website. Should take about 15 to 20 minutes and after that we will follow on with a quick or say 10-15 minute Q&A session and I'll then pass back to Rick for closing remarks. If you'd like to ask a question, you can do so using the Q&A tab in the ribbon at the bottom of your screen, and we'll get through as many questions as we can in the time that we have. But for now, I'd like to hand over the floor to Rick, who will get us on the road. Thanks, Rick.

Okay. Thanks, Jane. Good morning, and I want to thank everyone for joining us this morning. My name is Rick Ratliff, and as Jane mentioned, I'm the CEO and Managing Director of MedAdvisor Solutions. This morning we're going to go through our first half update. And just to give you a sense of the flow, if we can go to the agenda slide, slide number two. You know, first we're going to spend some time, I'll spend a little bit of time taking you through a high-level view of the accomplishments in the first half of FY24. And then Ansel and I are actually gonna step you through our financial and operational update in much more detail. And then I'll take you through a discussion on our plans for investment in our future growth. And then finally, we'll wrap up with a view on our outlook for the second half of FY24 and beyond. So let's take a look at the overview of the first half. If we'll go to slide four. For those of you that are fairly new to our business, just real fast, MedAdvisor Solutions is a global leader of pharmacy-driven patient engagement solutions. We provide individualized experiences for patients which help with removing barriers to care. That's our primary focus. We'll talk a little bit more about that as we get into the strategy. But for the highlights for the half, we recorded record revenue of $75.5 million for the half. This number was up 18% in comparison to the same period in the prior year. And we managed to achieve these revenues with a gross margin of 57.6%. So we're really pleased with the results and we'll talk in more detail on those in just a minute. Also at a high level, our vaccine program revenue diversified substantially in the half. We now are delivering programs across seven vaccine categories and vaccine programs representing about 55% of our U.S. revenue in the first half. In addition, the full impact of the FY23 GuildLink acquisition has come through and an outstanding 95% of Australian pharmacies are now running our software. This and price increase implemented in FY23 drove excellent growth in our software-as-a-service revenue, which was up 15.5% on the prior corresponding period. Also, after extensive review of our UK operations, And the best way forward, we finalized an initial investment in the UK based Shrack and we'll talk a little bit more about Shrack later, but this has allowed us to scale back our own UK operations and associated fixed costs associated with those operations, but it's also creating an opportunity for MedAdvisor to expand our services at a faster pace and lower cost in the UK, ANC, as well as the US. And like I said, we'll talk more about that later in the presentation. So we were selected as the preferred software provider for the North Queensland Community Pharmacy Scope of Practice pilot. You've probably heard some about this. We're very excited about the opportunity this has followed. on from the successful UTI and oral contraceptive programs that we've run with pharmacies in Queensland, North South Wales, Western Australia, and Victoria. It's establishing a platform for us for growth in Australia, New Zealand, as we'll talk about more today, but in FY25, FY26, and beyond. Finally, we've completed our planning for our five-year growth strategy. And there's a section in the presentation later where we'll talk more about our plan to invest, how we're going to drive further stability in our foundation and our cost basis to help us to create a framework for sustained profitable growth. So if we'll turn to slide five, we're now going to move into our first half financial and operational progress. And I'm gonna turn it over to Yancela who's gonna spend some time on the financials, starting with our group financial highlights for the first half of FY24. So Yancela, over to you.